替比夫定与拉米夫定治疗慢性乙型病毒性肝炎的疗效比较

Compare Efficacy of Telbivudine and Lamivudine in the Treatment Patients with Chronic Hepatitis B Virus

目的：探讨替比夫定与拉米夫定治疗慢性乙型病毒性肝炎的疗效。方法：回顾性分析我院2009年1月~2011年12月收治的200例慢性乙型肝炎患者的临床资料,将其随机分为拉米夫定组和替比夫定组,拉米夫定组服用拉米夫定600mg,1次/d口服治疗,替比夫定600mg,1次/d口服治疗,观察临床效果。结果：替比夫定组与拉米夫定组相比,HBV-DNA基线下降值、HBV-DNA低于检测下降、治疗应答、HBeAg转阴率、ALT复常率、病毒学应答率、原发治疗失数率均有显著性差异（P〈0.05）。结论：替比夫定属于一种核苷类似物,具有很强的抗HBV作用,其HBeAg血清学转换率比较高、发生比较早,并且具有很好的耐药性,值得推广。

Objective：To investigate the effects of telbivudine and lamivudine in treating chronic HBV.Methods：A retrospective analysis treated 200 cases of chronic hepatitis B patients with the clinical data,in our hospital in January 2009 to December 2011,were randomly divided into lamivudine telbivudine and lamivudine group,lamivudine for 600 mg,1/d oral treatment,in 600mg,1/d oral treatment,observation of clinical effect.Results：In the group with lamivudine group compared with the baseline,HBV-DNA decreased,HBV-DNA below detection,response to therapy,decrease negative conversion rate of HBeAg,ALT recovery,virological response rate,primary treatment failure rate had significant difference（P0.05）.Conclusion：Telbivudine is a strong resistance to HBV effects of nucleoside analogues,the HBeAg serological conversion rate is high,occur earlier,and drug resistance is good,worthy of promotion.